Market Overview

Autoinjectors Market Worth $85.31 Billion by 2023

Share:

Autoinjectors Market Worth $85.31 Billion by 2023

PR Newswire

PUNE, India, August 1, 2018 /PRNewswire/ --

According to a new market research report 'Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023', published by MarketsandMarkets™, the global market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023).

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Browse 66 market data Tables and 36 Figures spread through 133 Pages and in-depth TOC on 'Autoinjectors Market'

https://www.marketsandmarkets.com/Market-Reports/autoinjector-market-173991724.html

Early buyers will receive 10% customization on this report 

The key factors driving the growth of this market include the growing prevalence of targeted therapies such as rheumatoid arthritis and multiple sclerosis, rising incidence of anaphylaxis, and increasing number of regulatory approvals.

By therapy, the rheumatoid arthritis segment is expected to account for the largest share of the market in 2018 

On the basis of therapy, the Autoinjectors Market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies such as migraines, cardiovascular diseases, psoriasis, and anemia. In 2018, the rheumatoid arthritis segment is expected to account for the largest share of the global market. The large share of this segment can be primarily attributed to the high prevalence of rheumatoid arthritis across the globe.

By type, the disposable autoinjectors segment is expected to account for the largest share of the market in 2018 

On the basis of type, the Autoinjectors Market is segmented into disposable and reusable autoinjectors. In 2018, the disposable autoinjectors segment is expected to account for the largest share of the global market. The large share of this segment can be primarily attributed to their ease of use and minimal risk of infection.

By end user, the home care settings segment is expected to account for the largest share of the market in 2018 

On the basis of end user, the Autoinjectors Market is segmented into home care settings and hospitals & clinics. In 2018, home care settings segment is expected to account for the largest share of the global market. A majority of autoinjectors are used for self-administration of drugs and are rarely recommended for hospital use to avoid the risk of infection due to use on multiple patients. This is a major factor driving market growth. Other factors such as the growing prevalence of chronic diseases and technological advancements are also supporting growth in this market segment.

Ask for PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=173991724

North America to dominate the market in 2018 

In 2018, North America is expected to account for the largest share of the Autoinjectors Market, followed by Europe. Factors such as increasing geriatric population in Canada, increasing FDA approvals, rising prevalence of anaphylaxis in the US, and rising prevalence of autoimmune and chronic diseases in the US and Canada are contributing to the large share of North America.

The key players in the global Autoinjectors Market are Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US). The other prominent players in the market are J&J (US), Novartis (Switzerland), Bayer (Germany), Merck (Germany), Biogen (US), Ypsomed (Switzerland), SHL Group (Taiwan) Becton, Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), and Haselmeier (Switzerland).

Know more about the Autoinjectors Market: 

https://www.marketsandmarkets.com/Market-Reports/autoinjector-market-173991724.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the 'Growth Engagement Model - GEM'. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write 'Attack, avoid and defend' strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, 'Knowledge Store' connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Shelly Singh

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/autoinjector-market.asp

Connect with us on LinkedIn: http://www.linkedin.com/company/marketsandmarkets


SOURCE MarketsandMarkets

View Comments and Join the Discussion!